Mocetinostat: Phase II data

An open-label, U.S. Phase II trial in 66 patients with MDS or AML showed that thrice-weekly oral mocetinostat plus azacitidine led to an ORR, defined as complete remission (CR), CR with incomplete blood count recovery (CRi) or hematological improvement, of 61% in patients with high-risk MDS (n=28) and 32% in patients with AML (n=38). In patients with intermediate-2 or high-risk MDS (n=14), 64% achieved a CR or CRi. Additionally, the DCR was 93% in the MDS cohort and 84% in the AML cohort, while median OS was 12.9 months in the MDS cohort and 5.1 months in the AML cohort. Furthermore, 66% of all patients remained progression-free while on study. The most common treatment-related grade 3 or higher toxicities were fatigue, nausea, thrombocytopenia, anemia, diarrhea and vomiting. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...